Literature DB >> 23051059

Vaccination of immunocompromised patients.

Per Ljungman1.   

Abstract

Vaccination of immunocompromised patients is challenging both regarding efficacy and safety. True efficacy data are lacking so existing recommendations are based on immune responses and safety data. Inactivated vaccines can generally be used without risk but the patients who are most at risk for infectious morbidity and mortality as a result of their severely immunosuppressed state are also those least likely to respond to vaccination. However, vaccination against pneumococci, Haemophilus influenzae and influenza are generally recommended. Live vaccines must be used with care because the risk for vaccine-associated disease exists.
© 2012 The Author. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23051059     DOI: 10.1111/j.1469-0691.2012.03971.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  24 in total

Review 1.  Impact of host genetic polymorphisms on vaccine induced antibody response.

Authors:  Janina E Linnik; Adrian Egli
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

2.  CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection.

Authors:  Shabnam Alam; Zackery A G Knowlden; Mark Y Sangster; Andrea J Sant
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

Review 3.  Practical review of immunizations in adult patients with cancer.

Authors:  Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Hum Vaccin Immunother       Date:  2015-06-25       Impact factor: 3.452

4.  Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus.

Authors:  Virginie S Adam; Marco Crosariol; Sachin Kumar; Moyar Q Ge; Sarah E Czack; Soumitra Roy; Angela Haczku; Anna Tretiakova; James M Wilson; Maria P Limberis
Journal:  Clin Vaccine Immunol       Date:  2014-09-10

5.  Validation of γ-radiation and ultraviolet as a new inactivators for foot and mouth disease virus in comparison with the traditional methods.

Authors:  Safy El Din Mahdy; Amr Ismail Hassanin; Wael Mossad Gamal El-Din; Ehab El-Sayed Ibrahim; Hiam Mohamed Fakhry
Journal:  Vet World       Date:  2015-09-19

Review 6.  First International Precision Vaccines Conference: Multidisciplinary Approaches to Next-Generation Vaccines.

Authors:  Francesco Borriello; Simon D van Haren; Ofer Levy
Journal:  mSphere       Date:  2018-08-01       Impact factor: 4.389

7.  Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.

Authors:  Patrice Chevallier; Marianne Coste-Burel; Amandine Le Bourgeois; Pierre Peterlin; Alice Garnier; Marie C Béné; Berthe-Marie Imbert; Thomas Drumel; Steven Le Gouill; Philippe Moreau; Beatrice Mahe; Viviane Dubruille; Nicolas Blin; Anne Lok; Cyrille Touzeau; Thomas Gastinne; Maxime Jullien; Sophie Vanthygem; Thierry Guillaume
Journal:  EJHaem       Date:  2021-06-01

8.  COVID-19 Vaccination in Patients with Classic Kaposi's Sarcoma.

Authors:  Alice Indini; Athanasia Tourlaki; Francesco Grossi; Donatella Gambini; Lucia Brambilla
Journal:  Vaccines (Basel)       Date:  2021-06-10

Review 9.  Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.

Authors:  Marta López-Fauqued; Maribel Co-van der Mee; Adriana Bastidas; Pierre Beukelaers; Alemnew F Dagnew; Juan Jose Fernandez Garcia; Anne Schuind; Fernanda Tavares-da-Silva
Journal:  Drug Saf       Date:  2021-06-11       Impact factor: 5.606

Review 10.  New insights on the development of fungal vaccines: from immunity to recent challenges.

Authors:  Natasha P Medici; Maurizio Del Poeta
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11-24       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.